Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q2 2025 Pharma Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q2 2025 Pharma Services Update

Pharmaceutical Commercialization Subsector Highlight:

M&A activity within the pharmaceutical commercialization sector remained strong in Q2-25 with a total of 11 closed transactions. Despite a marginal decrease in QoQ deal volume and minimal platform creation activity by private equity sponsors, Provident anticipates strong future M&A volume driven by the near-term recapitalizations of several scaled, private equity-backed strategic operators.

PharmaCord’s merger with Mercalis emphasizes a broader trend of consolidation in the outsourced pharma services sector. Strategic players are increasingly looking to leverage technologies and AI to enhance service offerings. Datavant’s acquisition of Aetion, a leading real-world evidence (RWE) solutions provider, similarly demonstrates a growing demand for data-driven insights to support commercialization services.

To print and download the full Pharma Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2025/07/Q22025PharmaServicesUpdate.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]